Hi Hittman
Thats true but equally I think most of the share registry would give a resounding NO on anything in the 2 dollar range.
We're about to probably be making a billion dollars a year in profit and most Lithium companies are valued at EBITDA times 8 which is then divided by the shares on issue.
If we only use the pure profits figure (which is actually lower than the EBITDA) and times it by 8 your looking at 8 billion.
Divide that by the 1.8 billion shares now on issue since the CR and you arrive at a share price of 4.44. Thats not far from PLS current SP (Although as a PLS holder, I suspect they are going to continue to march up too).
Therefore, I cant see too many holders out there taking an offer in the 2 buck range when they know a measly 65 million could double production (and therefore revenues), that our LOM is likely to be north of 30 years at the end of 2023 and that we could have a Hydroxide deal on the table in 9 days.
Anything less than 3 bucks I feel would be regarded by most as strongly taking the micky.
- Forums
- ASX - By Stock
- CXO
- Banter and general comments
Banter and general comments, page-15631
-
- There are more pages in this discussion • 23,490 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CXO (ASX) to my watchlist
|
|||||
Last
9.4¢ |
Change
0.002(2.17%) |
Mkt cap ! $196.5M |
Open | High | Low | Value | Volume |
9.4¢ | 9.4¢ | 9.4¢ | $154.1K | 1.640M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
11 | 841969 | 9.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.4¢ | 519966 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 68535 | 0.096 |
4 | 281197 | 0.095 |
3 | 196170 | 0.094 |
6 | 690600 | 0.093 |
17 | 2063892 | 0.092 |
Price($) | Vol. | No. |
---|---|---|
0.046 | 97 | 3 |
0.087 | 119213 | 2 |
0.090 | 26414 | 1 |
0.091 | 80000 | 1 |
0.092 | 141462 | 6 |
Last trade - 10.02am 14/08/2024 (20 minute delay) ? |
Featured News
CXO (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
SPONSORED BY The Market Online